Skip to main content
. 2023 Feb 1;15(3):918. doi: 10.3390/cancers15030918

Figure 4.

Figure 4

RIPK4 overexpression in A375-dCas9 cells inhibits the RIPK4 diminishing effect of BRAFi but do not affect ERK1/2 activity. A375-dCas9 cells are transfected with two single sgRNAs targeting RIPK4 (RIPK4.sg1, RIPK4.sg2) or no targeting control (neg.sg). After 72 h of transfection, cells were incubated with vemurafenib (PLX; 10 µM) and dabrafenib (GSK; 10 nM), or DMSO, as a control, for 48 h. (a,b) The expression levels of RIPK4, P-ERK1/2, and ERK1/2 were analyzed using Western blot along with densitometry. GAPDH was used as a loading control. (c) MTT assay after 24 h. Each bar represents the mean ± SD of three biological replicates. * p < 0.05 and ** p < 0.01 were considered significant.